| |
Wednesday, August 7, 2024 | 11am ET / 8am PT Join us for this one-hour, deep dive to learn more about the rise of dynamic modular content as today's leading engagement strategy. Discover how this innovative digital design system is helping increase patient medication adherence and the length of therapies. 
|
|
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today! 
|
|
| By Zoey Becker While President Joe Biden is officially out for the 2024 election, his term has certainly made a mark in the healthcare realm. |
|
|
|
By Nick Paul Taylor A clutch of Johnson & Johnson veterans have burst onto the biotech scene, launching Third Arc Bio with $165 million to take multifunctional antibodies into the clinic in solid tumors and autoimmune diseases. |
By Nick Paul Taylor Innovent has pulled off another late-phase win for its Eli Lilly-partnered GLP-1 drug candidate, linking the dual agonist to improved outcomes in type 2 diabetes to tee up a filing for approval in China. |
By Angus Liu A new 42-acre campus in New Jersey gives BeiGene CEO John Oyler hope that the company can strike new partnerships in biologics. |
|
Wednesday, August 14, 2024 | 1pm ET / 10 am PT Join our webinar to discover how you can use generative AI and other forms of AI to expedite early research and speed up drug discovery and development, using a purpose-built, highly secure, high performance computing (HPC) infrastructure in the cloud. 
|
|
By Conor Hale Named DORA, the manuscript helper taps multiple AI and large language models to support the drafting of academic papers and case studies, in addition to applications for grants and patents. |
By Darren Incorvaia When it comes to developing new pain drugs, the placebo effect is a powerful but baffling force. Researchers have successfully mapped the neural circuits responsible for placebo pain relief in mice. |
By Angus Liu While the international IT outage caused by cybersecurity specialist CrowdStrike—and subsequently Microsoft—has grounded airlines and forced cancelations at hospitals, the experience from the meltdown appeared different at large pharma companies. |
By Nick Paul Taylor Takeda’s resurrection of the once-rejected Eohilia appears to be paying off, with a survey of physicians finding the launch is in line with the rollout of Dupixent and is delaying the use of Regeneron and Sanofi’s blockbuster. |
By Nick Paul Taylor Morphic only had eyes for Eli Lilly. While some takeover tales have casts of Shakespearean breadth, Lilly’s $3.2 billion Morphic buyout is a simpler story of two companies gradually closing the gap between their positions before tying the knot. |
By Kevin Dunleavy Pfizer has opened an extension to its active pharmaceutical ingredient (API) plant in Singapore. The SGD $1 billion ($743 million) project covers 429,000 square feet and will produce antibiotics and small molecules to treat cancer and pain, the company said. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “Podnosis,” Micky Tripathi, Ph.D., National Coordinator for Health Information Technology at HHS, chats with Executive Editor Heather Landi about ONC’s achievements over the past 20 years, the agency’s current top priorities, the rapid adoption of AI in healthcare and more. |
|
|---|
|
|
|
Wednesday, August 21, 2024 | 12pm ET / 9am PT Join us to explore the critical stages of clinical trials, demonstrating how data-driven solutions can enhance each phase for optimal outcomes. Whether you're initiating a new study or looking to enhance ongoing trials, this webinar will provide valuable strategies and tools to elevate your clinical research initiatives. Register now. 
|
|
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper Self-amplifying RNAs (also known as self-replicating RNAs), or saRNAs, are increasing in popularity as a platform for vaccine development. Download to learn how to make a more streamlined and efficient manufacturing of self-amplifying RNAs. Sponsored by: TriLink |
Whitepaper An insider’s workbook filled with practical tips and tools for designing and scaling a global patient support program. Sponsored by: Harte Hanks |
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper When we talk about digital twins in the context of biology and medicine, we're inherently discussing a simplified model. These simplifications aren't a drawback but a necessity. Sponsored by: Unlearn |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper This study delved into the manufacturing costs of the three mRNA capping methods. It involved discussions with 30 subject matter experts engaged in mRNA therapeutic development across various companies in the US and the EU. Sponsored by: TriLink |
Research Learn how a Top-10 Pharma company automated the extraction of oncology efficacy endpoints from scientific literature with high precision and recall using a combination of AI technologies. Sponsored by: IQVIA |
Whitepaper Small molecule active pharmaceutical ingredients (APIs) continue to grow more complex. Download the white paper to learn more about using synthesis and route design technology to approach API complexity. Sponsored by: Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
